Current management and novel therapeutic strategies for refractory ascites and hepatorenal syndrome.

H Suzuki, A J Stanley

Journal: QJM : monthly journal of the Association of Physicians 2001;94(6):293-300

PMID: 11391027

Full Text on Ovid Technologies, Inc. View on PubMed

Abstract

The circulatory disturbances seen in advanced cirrhosis lead to the development of ascites, which can become refractory to diet and medical therapy. These abnormalities may progress and cause a functional renal failure known as the hepatorenal syndrome. Management of refractory ascites and hepatorenal syndrome is a therapeutic challenge, and if appropriate, liver transplantation remains the best treatment. New therapeutic options have recently appeared, including the transjugular intrahepatic portosystemic shunt and selective splanchnic vasoconstrictor agents, which may improve renal function and act as a bridge to transplantation.

Address: Department of Gastroenterology, Glasgow Royal Infirmary, 84 Castle Street, Glasgow G4 0SF, UK.

DOI: 10.1093/qjmed/94.6.293

Link outs

Free resources

Medical:

https://clinicaltrials.gov/search?term=AREA%5BRefe...

Other Literature Sources:

https://www.lens.org/lens/search/patent/list?q=ref...

Subscription / membership required

Full Text Sources:

MeSH Terms: Ascites, Atrial Natriuretic Factor, Cardiotonic Agents, Dopamine, Hepatorenal Syndrome, Humans, Liver Transplantation, Paracentesis, Peritoneovenous Shunt, Portasystemic Shunt, Transjugular Intrahepatic, Prostaglandins, Synthetic, Vasoconstrictor Agents